$695 | Single User
$1395 | Global License

Physician Views: Will an Opdivo/Yervoy combination succeed in melanoma and can Keytruda keep pace in non-small-cell lung cancer?
[Lowest Price Guaranteed: $695]

Published by FirstWord Pharma: 23 Apr 2015 | 213 | In Stock
Related Topics: Cancer , FDA

Introduction

Scope



New data presented at the annual meeting of the American Association for Cancer Research (AACR) this past week has further emphasised the paradigm shift in cancer therapy that PD-1 inhibitors offer.


Focusing on the two most advanced products in this class – Bristol-Myers Squibb's Opdivo and Merck & Co.'s Keytruda – FirstWord is polling US and EU5-based oncologists this week to gauge opinion towards two specific areas of future usage.


In the melanoma market, where both products are already approved as second-line therapies, Bristol-Myers Squibb demonstrated further evidence that Opdivo, when used in combination with its CTLA-4 inhibitor Yervoy, was significantly more effective than Yervoy alone for first-line therapy. Indeed, the Checkmate-069 study demonstrated that in first-line stage III and stage IV melanoma patients, the combination triggered an objective response rate of 61 percent versus 11 percent for Yervoy monotherapy (ViewPoints: Bristol-Myers Squibb ups the stakes with combination melanoma play).


Retaining a first-line presence for the Yervoy franchise in melanoma will be key in allowing Bristol-Myers Squibb to build a franchise position in this indication and meet consensus revenue forecasts. Nevertheless, increased efficacy comes with a notably increased toxicity profile, with 54 percent of combination-treated patients suffering from grade 3 or 4 adverse reactions versus 17 percent of those patients treated with just Yervoy


Puchase Reasons


Quite how this combination will fit into the treatment paradigm remains to be seen, and we are asking oncologists to estimate (based on the Phase II data)…


  • What percentage of first-line patients they would anticipate being treated initially with the combination of Opdivo and Yervoy?

  • What percentage of first-line patients they would expect to be initially treated with a more flexible regimen, such as Opdivo with subsequent addition of Yervoy if necessary?

  • What impact they expect the side-effect profile for the combination of Opdivo and Yervoy to have in limiting use of this combination in the first-line setting?

  • Switching focus to the second-line treatment of non-small-cell lung cancer, Bristol-Myers Squibb and Merck both continue to demonstrate impressive manoeuvrability in moving Opdivo and Keytruda, respectively, faster to market than expected. With Bristol-Myers Squibb's Checkmate-057 stopped early, Opdivo has now demonstrated survival benefit in both squamous and non-squamous patients, while Keytruda has been filed as a second-line therapy on the strength of data from the Keynote-001 study, Merck confirmed last week (ViewPoints: Merck & Co. ups its game again, but Bristol-Myers Squibb takes lead in NSCLC PD-1 race).


    Notably, the FDA has confirmed that it will not require overall survival data for Keytruda prior to approval, which appears to not only remove any overhang that Opdivo could quickly raise barriers to entry in the lung cancer indication, but confirm that Merck – to some extent – will continue to 'piggy-back' on Bristol-Myers Squibb's first-to-market status. A key question is whether this extend to labelling and usage of Keytruda, given that the Keynote-001 study stratified patients by PD-L1 biomarker status (while Opdivo – in the second-line setting at least – has been studied in 'all comers').


    On this issue, we are asking oncologists…


  • To provide their assessment of available data to ascertain whether either Opdivo or Keytruda is more strongly positioned in the second-line NSCLC market?

  • Whether initial usage of Keytruda will occur in all second-line NSCLC patients or just PD-L1 over expressers, and how labelling and or study design may dictate this?
  • Table of Contents
    for Physician Views: Will an Opdivo/Yervoy combination succeed in melanoma and can Keytruda keep pace in non-small-cell lung cancer?

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    213 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Will an Opdivo/Yervoy combination succeed in melanoma and can Keytruda keep pace in non-small-cell lung cancer? | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...